ArticleThe neuroradiology journal2016
Is size an essential criterion to define tumefactive plaque? MR features and clinical correlation in multiple sclerosis.
Article in The neuroradiology journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 34 citations in OpenAlex.
- Tumefactive Demyelination in Older Adults: Diagnosis and Misdiagnosis.International journal of MS care · 2025Article
- Article
- Tumor-like Lesions in Primary Angiitis of the Central Nervous System: The Role of Magnetic Resonance Imaging in Differential Diagnosis.Diagnostics (Basel, Switzerland) · 2024Review
- Tumefactive demyelinating lesions: a retrospective cohort study in Thailand.Scientific reports · 2024Article
- A rare case of tumefactive demyelination of brain: A case report and literature review.Clinical case reports · 2023Article
- Clinical spectrum and prognosis of pathologically confirmed atypical tumefactive demyelinating lesions.Scientific reports · 2023Article
- Oral Health Status and Multiple Sclerosis: Classic and Non-Classic Manifestations-Case Report.Diseases (Basel, Switzerland) · 2022Article
- Population-based incidence and clinico-radiological characteristics of tumefactive demyelination in Olmsted County, Minnesota, United States.European journal of neurology · 2022Article
- Central nervous system tumefactive demyelinating lesions: Risk factors of relapse and follow-up observations.Frontiers in immunology · 2022Article
- When tumefactive demyelination is truly a tumor: case report of a radiographic misdiagnosis.CNS oncology · 2021Article
- Imaging in Pediatric Multiple Sclerosis : An Iconographic Review.Clinical neuroradiology · 2021Review
- Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques.The neuroradiology journal · 2019Article
- Article
- A Blind Spot in the Diagnostic Field: The Challenging Diagnosis of Tumefactive Multiple Sclerosis.Case reports in neurological medicine · 2018Article
- Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumefactive multiple sclerosis is an inflammatory demyelinating disease of the central nervous system. It has recently been described as a rare subtype of multiple sclerosis (MS) characterised by the appearance of solitary or multiple space-occupying lesions associated with imaging characteristics mimicking neoplasm. Atypical features include plaque size >2 cm with mass effect, oedema, and/or ring enhancement on magnetic resonance (MR) images.This study is a retrospective review designed to evaluate the prevalence of tumefactive plaques in a selected population of 440 MS patients referred to our MS centre in Southern Italy between 2005 and 2014. We analysed the radiographic features of lesions ranging in size from 0.5 to 2 cm to establish whether smaller plaques with MR characteristics similar to tumefactive plaques present different symptoms, disease evolution and prognosis. We also aimed to ascertain if MR features suggestive of biological aggressiveness could be useful prognostic criteria for a correct diagnosis of the disease and subsequent treatment. Our data suggest that lesions 0.5-2 cm and >2 cm have similar MR features and clinical evolution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.